MTOR and breast carcinoma: Accordingly, the primary objective of the present study was to develop a breast cancer mouse model that is cyclically administered cyclophosphamide (a potent standalone antitumour agent) and simultaneously provided an ovarian protective agent, rapamycin (an mTOR inhibitor known for its antitumour properties).